Retraction
Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the Co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment
Paper Information
Record ID:
35148
Author(s):
Journal:
Publication Date:
November 20, 2020
Retraction Date:
February 01, 2022
(3.8 years years ago)
Subjects:
Institution:
Department of General Surgery, Tongde Hospital of Zhejiang Province, Hangzhou, 310012, Zhejiang Province, ChinaCountry:
🇨🇳 ChinaArticle Type:
Publisher:
Springer
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Citations (13)
13
Total Citations7
Post-Retraction(53.8%)
6
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
0
Within 30 days
3
Within 1 year
2
After 2+ years
1072
Days since retraction (latest)
Could Drug Delivery Systems Be Enhancers for Therapy against KRAS-driven Cancers?
Ramil Khusnutdinov
Reviews and Advances in Chemistry
Published: Jan 2025
1072 days after retraction
Paper citing Nanoformulation of Apolipoprotein E3-Tagged Liposo...
Unknown Authors
Unknown Journal
Published: Oct 2024
973 days after retraction
Recent advances in liposome-based targeted cancer therapy
Yeliz Fidan, Stela Muçaj, Selin Seda Timur et al. (4 authors)
Journal of Liposome Research
Published: Oct 2023
36 citations
36 citations
616 days after retraction
Syntheses and evaluation of acridone derivatives as anticancer agents targeting Kras promoter i-motif structure
Zu‐Zhuang Wei, Xiaomin Lin, Siyi Wang et al. (9 authors)
Bioorganic Chemistry
Published: Apr 2023
9 citations
9 citations
430 days after retraction
Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer
Zhe Liu, Neha Parveen, Urushi Rehman et al. (10 authors)
Molecular Cancer
Open Access
Published: Jan 2023
55 citations
55 citations
345 days after retraction
Liposome-based diagnostic and therapeutic applications for pancreatic cancer
Faisal Raza, Lauren Evans, Mahzad Motallebi et al. (12 authors)
Acta Biomaterialia
Open Access
Published: Dec 2022
58 citations
58 citations
314 days after retraction
Pancreatic cancer and oligonucleotide therapy: Exploring novel therapeutic options and targeting chemoresistance
Apostolis Papaefthymiou, Aris Doukatas, Michail Galanopoulos
Clinics and Research in Hepatology and Gastroenterology
Published: Mar 2022
7 citations
7 citations
52 days after retraction
Lipid-based Nanoparticles for the Targeted Delivery of Anticancer Drugs: A Review
Mehrdad Moosazadeh Moghaddam, Hamed Khodaverdi, Maryam Shokrian Zeini et al. (6 authors)
Current Drug Delivery
Published: Jan 2022
11 citations
11 citations
14 days before retraction
Nano Phytoceuticals: A Step Forward in Tracking Down Paths for Therapy Against Pancreatic Ductal Adenocarcinoma
Shruti Gupta, Kiran Kumar Tejavath
Journal of Cluster Science
Published: Jan 2022
13 citations
13 citations
21 days before retraction
Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy
Sepideh Mirzaei, Mohammad Gholami, Hui Li Ang et al. (12 authors)
Cells
Open Access
Published: Nov 2021
47 citations
47 citations
64 days before retraction
RNAi-Based Approaches for Pancreatic Cancer Therapy
Min Ju Kim, Hyeyoun Chang, Gi‐Hoon Nam et al. (7 authors)
Pharmaceutics
Open Access
Published: Oct 2021
17 citations
17 citations
116 days before retraction
Employing siRNA tool and its delivery platforms in suppressing cisplatin resistance: Approaching to a new era of cancer chemotherapy
Sepideh Mirzaei, Mohammad Gholami, Farid Hashemi et al. (14 authors)
Life Sciences
Published: Mar 2021
92 citations
92 citations
310 days before retraction
Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine–Combination Therapy
Saffiya Habib, Moganavelli Singh
Nanomaterials
Open Access
Published: Feb 2021
36 citations
36 citations
339 days before retraction
Quick Stats
Total Citations:
13
Years Since Retraction:
3.8 years
Open Access:
Yes
Last Checked:
Jul 24, 2025